How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Core Viewpoint - Corbus Pharmaceuticals (CRBP) has shown a significant price increase of 26.8% over the past four weeks, with a mean price target of $42 indicating a potential upside of 318.3% from the current price of $10.04 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $8.99, where the lowest estimate is $28.00 (178.9% increase) and the highest is $53.00 (427.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - There is increasing optimism among analysts about CRBP's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - Over the last 30 days, two earnings estimates have been revised higher, leading to a 14% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - CRBP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]